NexMed, Inc (NEXM), a developer of innovative transdermal products, announced that Jay Birnbaum Ph.D. has joined the Company’s Scientific Advisory Board. As a result, NexMed’s board of directors has now increased to include four scientific leaders.

Dr. Birnbaum currently serves a medical research consultant, focused on ethical and OTC dermatologicals, devices, and cosmeceuticals. Prior to establishing his consulting company in 1999, Dr. Birnbaum was employed by Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President of Global Project Management. During that time period, Dr. Birnbaum was responsible for oversight and management of Novartis’s dermatology projects.

Dr. Birnbaum earned his Ph.D. in Pharmacology from the University of Wisconsin and a B.S. degree in Biology from Trinity College.

Vivian Liu, Chief Executive Officer, stated, “We are pleased to welcome Jay to our Scientific Advisory Board chaired by Dr. David Tierney. Jay was involved in the development of our anti-fungal product which is now in pivotal Phase 3 trials. As part of our Scientific Advisory Board, we are delighted that Jay will now play an even more active part in the continued development and expansion of our product pipeline.”

Let us hear your thoughts below: